Jens Meiler (Chemistry), Craig Lindsley (Pharmacology), and Heidi Hamm (Pharmacology) have created a new series of drug candidates against a hard-to-target receptor involved in the formation of blood clots. The research was published in ACS Pharmacology and Translational Science.

The Warren Center for Neuroscience and Drug Discovery hosts inaugural Open House event on May 30th.

WCNDD is featured in MyVU News!

Research led by David Merryman, a professor of biomedical engineering, pharmacology and medicine who holds the Walters Family Chair, has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects.

WCNDD Director of Outreach and Advocacy Programs, Kristen Gilliland, in the spotlight! Huge thank you to everyone who came out to the Franklin Theatre on Tuesday, August 15th to support her efforts. It was a huge success for everyone involved. Check out the full article below!

Vanderbilt documentary ‘Speaking Through Me’ spotlights youth brain education for mental health and substance use disorder prevention | Vanderbilt University

Grant aids drug discovery for autism, schizophrenia

With the aid of a four-year, $2.7 million grant from the National Institute of Mental Health, part of the National Institutes of Health (NIH), Vanderbilt University Medical Center pharmacologist Jerod Denton, PhD, and his team will pave the way for potential treatments for schizophrenia and autism spectrum disorder (ASD).

WCNDD Executive Director, Craig Lindsley, joins CAS Life Sciences Advisory Board. The board will guide the expanded CAS drug discovery journey to empower better decisions early in the drug discovery process. Read full press release at CAS convenes life sciences advisory board to reimagine the future of scientific discovery | CAS.